SCHEMBL16480599

SCHEMBL16480599

CC(C)(C)C(=O)SCCOP1(=O)OC[C@H]2O[C@@H](n3ccc(N)nc3=O)[C@](C)(Cl)[C@@H]2O1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 5/20 0.47
▸ PDE3A Q14432 3/20 0.37
▸ PDE4D Q08499 1/20 0.37
▸ SLC29A1 Q99808 1/20 0.37
▸ POLA1 P09884 1/20 0.34
▸ LMNA P02545 3/20 0.33
▸ CACNA1F O60840 2/20 0.33
▸ ALB P02768 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ CACNA1D Q01668 2/20 0.33
▸ CACNA1S Q13698 2/20 0.33
▸ CACNA1C Q13936 2/20 0.33
▸ POLG P54098 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ MTOR P42345 1/20 0.32
▸ MDM2 Q00987 1/20 0.32
▸ NCOA1 Q15788 1/20 0.32
▸ NCOA3 Q9Y6Q9 1/20 0.32
▸ FGFR1 P11362 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16480783 1.00 STING1 (0.47) STING1PDE3APDE4DSLC29A1POLA1
SCHEMBL16480807 1.00 STING1 (0.47) STING1PDE3APDE4DSLC29A1POLA1
SCHEMBL18263863 0.91 STING1 (0.48) STING1PDE3APDE4DSLC29A1POLA1
SCHEMBL16480818 0.85 STING1 (0.43) STING1POLA1
SCHEMBL16480483 0.85 STING1 (0.43) STING1POLA1
SCHEMBL16480820 0.85 STING1 (0.43) STING1POLA1
SCHEMBL17635345 0.83 STING1 (0.40) STING1PDE3APDE4DSLC29A1POLA1
SCHEMBL17635343 0.83 STING1 (0.40) STING1PDE3APDE4DSLC29A1POLA1
SCHEMBL17635344 0.83 STING1 (0.40) STING1PDE3APDE4DSLC29A1POLA1
SCHEMBL20221805 0.82 STING1 (0.46) STING1PDE3APDE4DSLC29A1POLA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2906579-B1 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION IDENIX PHARMACEUTICALS LLC (US) 2018-04-18 — — EP disclosed
US-20160083413-A1 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION IDENIX PHARMACEUTICALS LLC 2016-03-24 — — US disclosed
US-20160083413-A1 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION IDENIX PHARMACEUTICALS LLC 2016-03-24 — — US disclosed
WO-2014058801-A1 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION IDENIX PHARMACEUTICALS, INC. (US) 2014-04-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160083413-A1 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION SLC28A2, SLC28A1, SLC29A2 STING1 812/4885PDE3A 1190/4885PDE4D 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback